EGFR and neoplasm: More particularly, genetic modification (glycosylation) of PD-L1 that is induced by cancer cells via EGFR/B3GNT3 axis suppresses this tumor-suppressive effect of autophagy-mediated PD-L1 degradation, promoting tumor growth and evasion of immune surveillance mechanism in breast cancer models [63].